Epigenomics

Epigenomics Dividend Coverage

Dividend Coverage Ratio of Epigenomics (ECX.F) as of Oct 17, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Epigenomics is 2026 - . Dividend Coverage Ratio of Epigenomics was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Epigenomics Stock analysis

What does Epigenomics do? Epigenomics AG is a molecular diagnostics company headquartered in Berlin, Germany, specializing in the development and commercialization of proprietary products for cancer screening and diagnosis. The firm operates in Europe and the United States, focusing on blood-based diagnostic solutions for multiple cancer indications. Its primary product is Epi proColon, a blood test designed for colorectal cancer screening. Additionally, the company offers Epi proLung, a test that detects lung cancer in blood plasma. Beyond diagnostic kits, Epigenomics provides services related to research, product development, regulatory approval, and the manufacturing of in-vitro diagnostic products. The company went public on July 19, 2004, and currently employs 37 full-time staff members. Epigenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Epigenomics stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Epigenomics since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Epigenomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Epigenomics

All Key Metrics — Epigenomics